Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about ULTOMIRIS for Generalized Myasthenia Gravis (gMG) in the seven major markets.
A detailed picture of the ULTOMIRIS for generalized myasthenia gravis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ULTOMIRIS for generalized myasthenia gravis.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for generalized myasthenia gravis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in generalized myasthenia gravis.
Drug Summary
ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete, and sustained complement inhibition. It is administered intravenously every 8 weeks in adult patients, following a loading dose. ULTOMIRIS is approved in the US for the treatment of certain adults with gMG.
ULTOMIRIS (ravulizumab) works by inhibiting the C5 protein in the terminal complement cascade, a part of the body's immune system. When activated uncontrollably, the complement cascade over-responds, leading the body to attack its healthy cells.
In-depth ULTOMIRIS Market Assessment
This report provides a detailed market assessment of ULTOMIRIS for generalized myasthenia gravis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
ULTOMIRIS Clinical Assessment
The report provides the clinical trials information of ULTOMIRIS for generalized myasthenia gravis covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for generalized myasthenia gravis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ULTOMIRIS dominance.
- Other emerging products for generalized myasthenia gravis are expected to give tough market competition to ULTOMIRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ULTOMIRIS in generalized myasthenia gravis.
- This in-depth analysis of the forecasted sales data of ULTOMIRIS from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ULTOMIRIS in generalized myasthenia gravis.
Key Topics Covered:
1. Report Introduction
2. ULTOMIRIS Overview in Generalized Myasthenia Gravis
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Regulatory milestones
2.4. Other Developmental Activities
2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. ULTOMIRIS Market Assessment
5.1. Market Outlook of ULTOMIRIS in Generalized Myasthenia Gravis
5.2. 7MM Analysis
5.2.1. Market size of ULTOMIRIS in the 7MM for generalized myasthenia gravis
5.3. Country-wise Market Analysis
5.3.1. Market size of ULTOMIRIS in the United States for generalized myasthenia gravis
5.3.2. Market size of ULTOMIRIS in Germany for generalized myasthenia gravis
5.3.3. Market size of ULTOMIRIS in France for generalized myasthenia gravis
5.3.4. Market size of ULTOMIRIS in Italy for generalized myasthenia gravis
5.3.5. Market size of ULTOMIRIS in Spain for generalized myasthenia gravis
5.3.6. Market size of ULTOMIRIS in the United Kingdom for generalized myasthenia gravis
5.3.7. Market size of ULTOMIRIS in Japan for generalized myasthenia gravis
6. SWOT Analysis
7. Analysts' Views
For more information about this report visit https://www.researchandmarkets.com/r/3h3lh2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
